Skeletal Muscle Regulates Metabolism via Interorgan Crosstalk: Roles in Health and Disease

Journal of the American Medical Directors Association

Volumn 17, Issue 9, 2016, Pages 789-796

  Argilés, Josep M ^a   Campos, Nefertiti ^b   Lopez Pedrosa, José M ^b   Rueda, Ricardo ^b   Rodriguez Mañas, Leocadio ^c  

^a UNIVERSITY OF BARCELONA   (Spain)

^b ABBOTT LABORATORIES   (Spain)

^c HOSPITAL UNIVERSITARIO DE GETAFE   (Spain)

Author keywords

amino acid; glucose; HMB; Muscle; ONS; sarcopenia

Indexed keywords

AGING; CACHEXIA; HUMAN; MALNUTRITION; MUSCLE ATROPHY; MUSCLE FUNCTION; MUSCLE GROWTH; MUSCLE MASS; MUSCLE METABOLISM; MUSCLE STRENGTH; NUTRITION; PHYSICAL ACTIVITY; REVIEW; SARCOPENIA; SIGNAL TRANSDUCTION; SKELETAL MUSCLE; DIET; EXERCISE; FEMALE; MALE; METABOLISM; PHYSIOLOGY;

AMINO ACID; GLUCOSE;

AMINO ACIDS; DIET; EXERCISE; FEMALE; GLUCOSE; HUMANS; MALE; MUSCLE, SKELETAL;

EID: 84991833291     PISSN: 15258610     EISSN: 15389375     Source Type: Journal    
DOI: 10.1016/j.jamda.2016.04.019     Document Type: Review

References (95)

1. 1 Chromiak, J.A., Antonio, J., Skeletal muscle plasticity. Antonio, J., Kalman, D., Stout, J., (eds.) Essentials of Sports Nutrition and Supplements, 2008, Humana Press, Totowa, NJ.
2. 2 Shiozu, H., Higashijima, M., Koga, T., Association of sarcopenia with swallowing problems, related to nutrition and activities of daily living of elderly individuals. J Phys Ther Sci 27 (2015), 393–396.
3. 3 Meyer, C., Dostou, J.M., Welle, S.L., Gerich, J.E., Role of human liver, kidney, and skeletal muscle in postprandial glucose homeostasis. Am J Physiol Endocrinol Metab 282 (2002), E419–E427.
4. 4 Wolfe, R.R., The underappreciated role of muscle in health and disease. Am J Clin Nutr 84 (2006), 475–482.
5. 5 Frontera, W.R., Ochala, J., Skeletal muscle: a brief review of structure and function. Calcif Tissue Int 96 (2015), 183–195.
6. 6 Scott, W., Stevens, J., Binder-Macleod, S.A., Human skeletal muscle fiber type classifications. Phys Ther 81 (2001), 1810–1816.
7. 7 Matsakas, A., Patel, K., Skeletal muscle fibre plasticity in response to selected environmental and physiological stimuli. Histol Histopathol 24 (2009), 611–629.
8. 8 Shrayyef, M., Gerich, J., Normal glucose homeostasis. Poretsky, L., (eds.) Principles of Diabetes Mellitus, 2nd ed, 2010, Springer, New York, NY, US.
9. 9 Perriello, G., Nurjhan, N., Stumvoll, M., et al. Regulation of gluconeogenesis by glutamine in normal postabsorptive humans. Am J Physiol 272 (1997), E437–E445.
10. 10 Schiaffino, S., Reggiani, C., Fiber types in mammalian skeletal muscles. Physiol Rev 91 (2011), 1447–1531.
11. 11 Eken, T., Gundersen, K., Electrical stimulation resembling normal motor-unit activity: effects on denervated fast and slow rat muscles. J Physiol 402 (1988), 651–669.
12. 12 Pette, D., The adaptive potential of skeletal muscle fibers. Can J Appl Physiol 27 (2002), 423–448.
13. 13 von Haehling, S., Morley, J.E., Anker, S.D., From muscle wasting to sarcopenia and myopenia: update 2012. J Cachexia Sarcopenia Muscle 3 (2012), 213–217.
14. 14 Tisdale, M.J., Catabolic mediators of cancer cachexia. Curr Opin Support Palliat Care 2 (2008), 256–261.
15. 15 Mittendorfer, B., Andersen, J.L., Plomgaard, P., et al. Protein synthesis rates in human muscles: Neither anatomical location nor fibre-type composition are major determinants. J Physiol 563 (2005), 203–211.
16. 16 Goodman, C.A., Kotecki, J.A., Jacobs, B.L., Hornberger, T.A., Muscle fiber type-dependent differences in the regulation of protein synthesis. PLoS One, 7, 2012, e37890.
17. 17 Ventadour, S., Attaix, D., Mechanisms of skeletal muscle atrophy. Curr Opin Rheumatol 18 (2006), 631–635.
18. 18 Li, H., Malhotra, S., Kumar, A., Nuclear factor-kappa B signaling in skeletal muscle atrophy. J Mol Med (Berl) 86 (2008), 1113–1126.
19. 19 Eley, H.L., Tisdale, M.J., Skeletal muscle atrophy, a link between depression of protein synthesis and increase in degradation. J Biol Chem 282 (2007), 7087–7097.
20. 20 Costamagna, D., Costelli, P., Sampaolesi, M., Penna, F., Role of inflammation in muscle homeostasis and myogenesis. Mediators Inflamm, 2015, 2015, 805172.
21. 21 Langen, R.C., Schols, A.M., Kelders, M.C., et al. Inflammatory cytokines inhibit myogenic differentiation through activation of nuclear factor-kappaB. FASEB J 15 (2001), 1169–1180.
22. 22 Winkler, M., Malone, A., Medical nutrition therapy for metabolic stress: Sepsis, trauma, burns, and surgery. Mahon, K., Raymond, J., Escott-Stump, S., (eds.) Krause's Food and the Nutrition Care Process, 2012, Elsevier, St Louis, MO.
23. 23 Fischer, M., JeVenn, A., Hipskind, P., Evaluation of muscle and fat loss as diagnostic criteria for malnutrition. Nutr Clin Pract 30 (2015), 239–248.
24. 24 Nelson, DL, Cox, MM, Lehninger Principles of Biochemistry. 6th ed, 2013, W. H. Freeman & Co, New York, NY, 884–900.
25. 25 Heyland, D.K., Stapleton, R.D., Mourtzakis, M., et al. Combining nutrition and exercise to optimize survival and recovery from critical illness: Conceptual and methodological issues. Clin Nutr, 2015, 10.1016/j.clnu.2015.07.003.
26. 26 Curtis, E., Litwic, A., Cooper, C., Dennison, E., Determinants of muscle and bone aging. J Cell Physiol 230 (2015), 2618–2625.
27. 27 Cruz-Jentoft, A.J., Baeyens, J.P., Bauer, J.M., et al. Sarcopenia: European consensus on definition and diagnosis: Report of the European working group on sarcopenia in older people. Age Ageing 39 (2010), 412–423.
28. 28 Clark, B.C., Manini, T.M., Functional consequences of sarcopenia and dynapenia in the elderly. Curr Opin Clin Nutr Metab Care 13 (2010), 271–276.
29. 29 Hirani, V., Blyth, F., Naganathan, V., et al. Sarcopenia is associated with incident disability, institutionalization, and mortality in community-dwelling older men: The Concord Health and Ageing in Men Project. J Am Med Dir Assoc 16 (2015), 607–613.
30. 30 Scott, D., Daly, R.M., Sanders, K.M., Ebeling, P.R., Fall and fracture risk in sarcopenia and dynapenia with and without obesity: The role of lifestyle interventions. Curr Osteoporos Rep 13 (2015), 235–244.
31. 31 Yu, S., Umapathysivam, K., Visvanathan, R., Sarcopenia in older people. Int J Evid Based Healthc 12 (2014), 227–243.
32. 32 Demling, R.H., Nutrition, anabolism, and the wound healing process: An overview. Eplasty, 9, 2009, e9.
33. 33 Cerri, A.P., Bellelli, G., Mazzone, A., et al. Sarcopenia and malnutrition in acutely ill hospitalized elderly: Prevalence and outcomes. Clin Nutr 34 (2015), 745–751.
34. 34 Friedman, J., Lussiez, A., Sullivan, J., et al. Implications of sarcopenia in major surgery. Nutr Clin Pract 30 (2015), 175–179.
35. 35 Wall, B.T., Dirks, M.L., van Loon, L.J., Skeletal muscle atrophy during short-term disuse: Implications for age-related sarcopenia. Ageing Res Rev 12 (2013), 898–906.
36. 36 Rizzoli, R., Reginster, J.Y., Arnal, J.F., et al. Quality of life in sarcopenia and frailty. Calcif Tissue Int 93 (2013), 101–120.
37. 37 Walston, J., Fried, L.P., Frailty and the older man. Med Clin North Am 83 (1999), 1173–1194.
38. 38 Carcaillon, L., Garcia-Garcia, F.J., Tresguerres, J.A., et al. Higher levels of endogenous estradiol are associated with frailty in postmenopausal women from the Toledo study for healthy aging. J Clin Endocrinol Metab 97 (2012), 2898–2906.
39. 39 Penninx, B.W., Kritchevsky, S.B., Newman, A.B., et al. Inflammatory markers and incident mobility limitation in the elderly. J Am Geriatr Soc 52 (2004), 1105–1113.
40. 40 Walston, J., McBurnie, M.A., Newman, A., et al. Frailty and activation of the inflammation and coagulation systems with and without clinical comorbidities: Results from the Cardiovascular Health Study. Arch Intern Med 162 (2002), 2333–2341.
41. 41 Alonso-Bouzon, C., Carcaillon, L., Garcia-Garcia, F.J., et al. Association between endothelial dysfunction and frailty: The Toledo Study for Healthy Aging. Age (Dordr) 36 (2014), 495–505.
42. 42 Rodriguez Manas, L., Determinants of frailty and longevity: Are they the same ones?. Nestle Nutr Inst Workshop Ser 83 (2015), 29–39.
43. 43 Rodriguez-Manas, L., Feart, C., Mann, G., et al. Searching for an operational definition of frailty: A Delphi method based consensus statement: The frailty operative definition-consensus conference project. J Gerontol A Biol Sci Med Sci 68 (2013), 62–67.
44. 44 Clegg, A., Young, J., Iliffe, S., et al. Frailty in elderly people. Lancet 381 (2013), 752–762.
45. 45 Collard, R.M., Boter, H., Schoevers, R.A., Oude Voshaar, R.C., Prevalence of frailty in community-dwelling older persons: A systematic review. J Am Geriatr Soc 60 (2012), 1487–1492.
46. 46 Rodriguez-Manas, L., Fried, L.P., Frailty in the clinical scenario. Lancet 385 (2015), e7–e9.
47. 47 Abizanda, P., Romero, L., Sanchez-Jurado, P.M., et al. Age, frailty, disability, institutionalization, multimorbidity or comorbidity. Which are the main targets in older adults?. J Nutr Health Aging 18 (2014), 622–627.
48. 48 Sourial, N., Bergman, H., Karunananthan, S., et al. Implementing frailty into clinical practice: A cautionary tale. J Gerontol A Biol Sci Med Sci 68 (2013), 1505–1511.
49. 49 Beaudart, C., Rizzoli, R., Bruyere, O., et al. Sarcopenia: Burden and challenges for public health. Arch Public Health, 72, 2014, 45.
50. 50 Janssen, I., Shepard, D.S., Katzmarzyk, P.T., Roubenoff, R., The healthcare costs of sarcopenia in the United States. J Am Geriatr Soc 52 (2004), 80–85.
51. 51 Bock, J.O., Konig, H.H., Brenner, H., et al. Associations of frailty with health care costs - results of the ESTHER cohort study. BMC Health Serv Res, 16, 2016, 128.
52. 52 Gariballa, S., Alessa, A., Sarcopenia: Prevalence and prognostic significance in hospitalized patients. Clin Nutr 32 (2013), 772–776.
53. 53 Joglekar, S., Nau, P.N., Mezhir, J.J., The impact of sarcopenia on survival and complications in surgical oncology: A review of the current literature. J Surg Oncol 112 (2015), 503–509.
54. 54 Abizanda, P., Sinclair, A., Barcons, N., et al. Costs of malnutrition in institutionalized and community-dwelling older adults: A systematic review. J Am Med Dir Assoc 17 (2016), 17–23.
55. 55 von Haehling, S., The wasting continuum in heart failure: From sarcopenia to cachexia. Proc Nutr Soc 74 (2015), 1–11.
56. 56 Stenvinkel, P., Carrero, J.J., von Walden, F., et al. Muscle wasting in end-stage renal disease promulgates premature death: established, emerging and potential novel treatment strategies. Nephrol Dial Transplant, 2015.
57. 57 Argiles, J.M., Cancer-associated malnutrition. Eur J Oncol Nurs 9 (2005), S39–S50.
58. 58 Argiles, J.M., Busquets, S., Stemmler, B., Lopez-Soriano, F.J., Cancer cachexia: Understanding the molecular basis. Nat Rev Cancer 14 (2014), 754–762.
59. 59 Argiles, J.M., Fontes-Oliveira, C.C., Toledo, M., et al. Cachexia: A problem of energetic inefficiency. J Cachexia Sarcopenia Muscle 5 (2014), 279–286.
60. 60 Baldwin, C.E., Bersten, A.D., Myopathic characteristics in septic mechanically ventilated patients. Curr Opin Clin Nutr Metab Care 18 (2015), 240–247.
61. 61 Guillet, C., Boirie, Y., Insulin resistance: A contributing factor to age-related muscle mass loss?. Diabetes Metab, 31, 2005 5S20–5S26.
62. 62 Martinez, B.P., Batista, A.K., Gomes, I.B., et al. Frequency of sarcopenia and associated factors among hospitalized elderly patients. BMC Musculoskelet Disord, 16, 2015, 108.
63. 63 Evans, W.J., Morley, J.E., Argiles, J., et al. Cachexia: A new definition. Clin Nutr 27 (2008), 793–799.
64. 64 Kalinkovich, A., Livshits, G., Sarcopenia—The search for emerging biomarkers. Ageing Res Rev 22 (2015), 58–71.
65. 65 Cruz-Jentoft, A.J., Landi, F., Schneider, S.M., et al. Prevalence of and interventions for sarcopenia in ageing adults: A systematic review. Report of the International Sarcopenia Initiative (EWGSOP and IWGS). Age Ageing 43 (2014), 748–759.
66. 66 Deutz, N.E., Bauer, J.M., Barazzoni, R., et al. Protein intake and exercise for optimal muscle function with aging: Recommendations from the ESPEN Expert Group. Clin Nutr 33 (2014), 929–936.
67. 67 Arentson-Lantz, E., Clairmont, S., Paddon-Jones, D., et al. Protein: A nutrient in focus. Appl Physiol Nutr Metab 40 (2015), 755–761.
68. 68 Calvani, R., Miccheli, A., Landi, F., et al. Current nutritional recommendations and novel dietary strategies to manage sarcopenia. J Frailty Aging 2 (2013), 38–53.
69. 69 Bauer, J., Biolo, G., Cederholm, T., et al. Evidence-based recommendations for optimal dietary protein intake in older people: A position paper from the PROT-AGE Study Group. J Am Med Dir Assoc 14 (2013), 542–559.
70. 70 Milne, A.C., Potter, J., Vivanti, A., Avenell, A., Protein and energy supplementation in elderly people at risk from malnutrition. Cochrane Database Syst Rev(2), 2009, CD003288.
71. 71 Girón, M., Vílchez, J., Salto, R., et al. Conversion of leucine to β-hydroxy-β-methylbutyrate by α-keto isocaproate dioxygenase is required for a potent stimulation of protein synthesis in L6 rat myotubes. J Cachexia, Sarcopenia, and Muscle 7 (2016), 68–78.
72. 72 Wilkinson, D.J., Hossain, T., Hill, D.S., et al. Effects of leucine and its metabolite beta-hydroxy-beta-methylbutyrate on human skeletal muscle protein metabolism. J Physiol 591 (2013), 2911–2923.
73. 73 Casperson, S.L., Sheffield-Moore, M., Hewlings, S.J., Paddon-Jones, D., Leucine supplementation chronically improves muscle protein synthesis in older adults consuming the RDA for protein. Clin Nutr 31 (2012), 512–519.
74. 74 Leenders, M., Verdijk, L.B., van der Hoeven, L., et al. Prolonged leucine supplementation does not augment muscle mass or affect glycemic control in elderly type 2 diabetic men. J Nutr 141 (2011), 1070–1076.
75. 75 Verhoeven, S., Vanschoonbeek, K., Verdijk, L.B., et al. Long-term leucine supplementation does not increase muscle mass or strength in healthy elderly men. Am J Clin Nutr 89 (2009), 1468–1475.
76. 76 Alon, T., Bagchi, D., Preuss, H.G., Supplementing with beta-hydroxy-beta-methylbutyrate (HMB) to build and maintain muscle mass: A review. Res Commun Mol Pathol Pharmacol 111 (2002), 139–151.
77. 77 Deutz, N.E., Pereira, S.L., Hays, N.P., et al. Effect of beta-hydroxy-beta-methylbutyrate (HMB) on lean body mass during 10 days of bed rest in older adults. Clin Nutr 32 (2013), 704–712.
78. 78 Fitschen, P.J., Wilson, G.J., Wilson, J.M., Wilund, K.R., Efficacy of beta-hydroxy-beta-methylbutyrate supplementation in elderly and clinical populations. Nutrition 29 (2013), 29–36.
79. 79 Kimball, S.R., Jefferson, L.S., Signaling pathways and molecular mechanisms through which branched-chain amino acids mediate translational control of protein synthesis. J Nutr 136 (2006), 227S–231S.
80. 80 Nissen, S., Sharp, R., Ray, M., et al. Effect of leucine metabolite beta-hydroxy-beta-methylbutyrate on muscle metabolism during resistance-exercise training. J Appl Physiol (1985) 81 (1996), 2095–2104.
81. 81 Pasiakos, S.M., Margolis, L.M., Orr, J.S., Optimized dietary strategies to protect skeletal muscle mass during periods of unavoidable energy deficit. FASEB J 29 (2015), 1136–1142.
82. 82 Portal, S., Eliakim, A., Nemet, D., et al. Effect of HMB supplementation on body composition, fitness, hormonal profile and muscle damage indices. J Pediatr Endocrinol Metab 23 (2010), 641–650.
83. 83 Szczesniak, K.A., Ostaszewski, P., Fuller, J.C. Jr., et al. Dietary supplementation of beta-hydroxy-beta-methylbutyrate in animals—a review. J Anim Physiol Anim Nutr (Berl) 99 (2015), 405–417.
84. 84 Wilson, G.J., Wilson, J.M., Manninen, A.H., Effects of beta-hydroxy-beta-methylbutyrate (HMB) on exercise performance and body composition across varying levels of age, sex, and training experience: A review. Nutr Metab (Lond), 5, 2008, 1.
85. 85 Van Koevering, M., Nissen, S., Oxidation of leucine and alpha-ketoisocaproate to beta-hydroxy-beta-methylbutyrate in vivo. Am J Physiol 262 (1992), E27–E31.
86. 86 Baier, S., Johannsen, D., Abumrad, N., et al. Year-long changes in protein metabolism in elderly men and women supplemented with a nutrition cocktail of beta-hydroxy-beta-methylbutyrate (HMB), L-arginine, and L-lysine. J Parenter Enteral Nutr 33 (2009), 71–82.
87. 87 Giron, M.D., Vilchez, J.D., Shreeram, S., et al. beta-Hydroxy-beta-methylbutyrate (HMB) normalizes dexamethasone-induced autophagy-lysosomal pathway in skeletal muscle. PLoS One, 10, 2015, e0117520.
88. 88 Burton, L.A., Sumukadas, D., Optimal management of sarcopenia. Clin Interv Aging 5 (2010), 217–228.
89. 89 Denison, H.J., Cooper, C., Sayer, A.A., Robinson, S.M., Prevention and optimal management of sarcopenia: A review of combined exercise and nutrition interventions to improve muscle outcomes in older people. Clin Interv Aging 10 (2015), 859–869.
90. 90 Morley, J.E., Pharmacologic options for the treatment of sarcopenia. Calcif Tissue Int 94 (2016), 319–333.
91. 91 Miller, B.F., Olesen, J.L., Hansen, M., et al. Coordinated collagen and muscle protein synthesis in human patella tendon and quadriceps muscle after exercise. J Physiol 567 (2005), 1021–1033.
92. 92 Pasini, E., Le Douairon Lahaye, S., Flati, V., et al. Effects of treadmill exercise and training frequency on anabolic signaling pathways in the skeletal muscle of aged rats. Exp Gerontol 47 (2012), 23–28.
93. 93 Wenz, T., Rossi, S.G., Rotundo, R.L., et al. Increased muscle PGC-1alpha expression protects from sarcopenia and metabolic disease during aging. Proc Natl Acad Sci U S A 106 (2009), 20405–20410.
94. 94 Bowen, T.S., Schuler, G., Adams, V., Skeletal muscle wasting in cachexia and sarcopenia: Molecular pathophysiology and impact of exercise training. J Cachexia Sarcopenia Muscle 6 (2015), 197–207.
95. 95 Dideriksen, K., Reitelseder, S., Holm, L., Influence of amino acids, dietary protein, and physical activity on muscle mass development in humans. Nutrients 5 (2013), 852–876.